Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Main Article Content

Jennifer Soung
Lisa Tiu
Karen Veverka
Chih-Ho Hong



Abstract not available.


Disclosures: Study sponspored by LEO Pharma.


Copyright 2018 SKIN

Most read articles by the same author(s)

1 2 > >>